Literature DB >> 18708269

The congenital myasthenic syndromes.

Jackie Palace1, David Beeson.   

Abstract

The congenital myasthenic syndromes (CMS) are rare inherited disorders of neuromuscular transmission characterised by fatigable muscle weakness. Thus far, genetic analysis has identified mutations in eleven different genes but it is clear that additional phenotypic subgroups exist where the underlying genetics has not yet been defined. Although each syndrome results from defective synaptic transmission at the neuromuscular junction, the patients show a variable set of phenotypes. Here, we provide a brief clinical review.

Entities:  

Mesh:

Year:  2008        PMID: 18708269     DOI: 10.1016/j.jneuroim.2008.05.030

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  19 in total

1.  Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

Authors:  D Lashley; J Palace; S Jayawant; S Robb; D Beeson
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Two cases of congenital myasthenic syndrome with vocal cord paralysis.

Authors:  Rashid Al-Shahoumi; Lauren I Brady; Jeremy Schwartzentruber; Mark A Tarnopolsky
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

3.  An ocular motility conundrum.

Authors:  Elizabeth Margaret McElnea; Kirk Stephenson; Bernie Lanigan; Ian Flitcroft
Journal:  BMJ Case Rep       Date:  2014-10-27

4.  [Neuromuscular signal transmission in adulthood. Current facets of acquired and hereditary disorders].

Authors:  A Abicht; S Kröger; B Schoser
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 5.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

6.  Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.

Authors:  Sarah Finlayson; Jacqueline Palace; Katsiaryna Belaya; Timothy J Walls; Fiona Norwood; Georgina Burke; Janice L Holton; Samuel I Pascual-Pascual; Judith Cossins; David Beeson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-02-27       Impact factor: 10.154

7.  Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.

Authors:  Pedro M Rodríguez Cruz; Jacqueline Palace; Hayley Ramjattan; Sandeep Jayawant; Stephanie A Robb; David Beeson
Journal:  Neurology       Date:  2015-09-22       Impact factor: 9.910

8.  Clinical features of the myasthenic syndrome arising from mutations in GMPPB.

Authors:  Pedro M Rodríguez Cruz; Katsiaryna Belaya; Keivan Basiri; Maryam Sedghi; Maria Elena Farrugia; Janice L Holton; Wei Wei Liu; Susan Maxwell; Richard Petty; Timothy J Walls; Robin Kennett; Matthew Pitt; Anna Sarkozy; Matt Parton; Hanns Lochmüller; Francesco Muntoni; Jacqueline Palace; David Beeson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-05-04       Impact factor: 10.154

9.  Electrophysiological study in neuromuscular junction disorders.

Authors:  Ajith Cherian; Neeraj N Baheti; Thomas Iype
Journal:  Ann Indian Acad Neurol       Date:  2013-01       Impact factor: 1.383

Review 10.  Inherited disorders of the neuromuscular junction: an update.

Authors:  Pedro M Rodríguez Cruz; Jacqueline Palace; David Beeson
Journal:  J Neurol       Date:  2014-10-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.